Three clinical trials centers now open for enrollment; two additional ones initiating
LOS ALTOS, Calif., January 9, 2020 -- Retrotope announced today that it has dosed its first
patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of the
inherited ataxias. RT001, a stabilized fatty acid drug, has been shown to reduce lipid
peroxidation leading to cell death in patients across a wide swath of degenerative diseases,
including FA. More information and a list of participating clinical sites for the current trial in FA
can be obtained at ClinicalTrials.gov http://bit.ly/2T2FWA5. With this trial, the company expands its pipeline of indications for RT001 which is currently being studied in a pivotal trial in another fatal, neurodegenerative disease, Infantile Neuroaxonal Dystrophy (INAD), which is fully enrolled.
View the entire Press Release HERE